IL-NUCLEAI
24.6.2021 17:19:04 CEST | Business Wire | Press release
Nucleai (www.nucleaimd.com ), a precision medicine company using AI-powered image analysis technology to support novel pathology-based biomarker development, and Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that they have entered into a long-term collaboration to leverage Nucleai's image analysis and biomarker discovery platform for several Merck KGaA, Darmstadt, Germany clinical stage oncology assets.
As part of the collaboration, Merck KGaA, Darmstadt, Germany will leverage Nucleai’s platform for exploratory research, with the potential to further develop identified pathology-based biomarkers as companion diagnostics. The collaboration will further utilize Nucleai’s technology to expand onto Merck KGaA, Darmstadt, Germany’s analysis capabilities, enabling faster turnaround time and scale for future studies.
Nucleai's platform analyzes tissue images using computer vision and machine learning methods to model the tumor and the immune system's spatial characteristics, creating unique and specific histological biomarkers that may help predict patient response. These biomarkers hold the potential to provide better understanding of cancer biology, enable further stratification of responder/non-responder patient populations, and improve the success rate of clinical trials and patient care. To develop its platform, Nucleai leverages proprietary datasets of pathology images and clinical data from leading hospitals and Health Maintenance Organizations (HMOs) in the U.S and Israel.
“We are thrilled to announce another major collaboration with a leading pharmaceutical company like Merck KGaA, Darmstadt, Germany to identify and develop novel biomarkers for their oncology assets. By combining real world and clinical trial datasets, with an integrated and scalable technology platform, we are harnessing the power of AI and big data and setting the standard for future precision medicine collaborations, adds Avi Veidman, CEO and Co-Founder of Nucleai.”
About Nucleai
Nucleai is a precision medicine company that has developed an AI-powered image analysis platform to unlock the power of spatial biology from pathology images. Nucleai’s ATOM platform, built and trained off large-scale proprietary datasets, leverages computer vision and deep neural networks to structure and characterize tissue and cell architecture in pathology images to identify spatial characteristics that predict response to therapy and inform treatment decision. We are currently partnered with leading pharmaceutical companies to discover novel spatial biomarkers, develop pathology-based companion diagnostics assays and drive improved patient outcomes. For more information, please visit www.nucleaimd.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005753/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Angelalign Technology Inc. (6699.HK) Applauds European Court Rejection of Patent Infringement Claim12.5.2026 19:39:00 CEST | Press release
Angelalign Technology Inc. (6699.HK) (“Angel”) (http://www.angelaligner.com) today said it was grateful that the Local Division Düsseldorf (Germany) of the Unified Patent Court rejected a request by Align Technology Inc. (ALGN) for Angel to cease and desist from using its A7 Premolar Extraction Solution. Angel denied that the A7 tooth movement protocol infringes any patents as alleged by Align Technology Inc. (ALGN). The court rejected Align’s request for Angel to preliminarily cease its use of the feature, a decision Angel applauded. “We respect the Düsseldorf Local Division’s ruling and will continue to make our case that Angel has not violated any valid patents,” said Dr. Arno Riße, Angel’s attorney at the Arnold Ruess law firm of Düsseldorf. “We are grateful that the court decided not to grant Align's request for preliminary measures. Angel takes intellectual property rights seriously and is careful not to infringe on legitimate patents.” “We categorically deny the allegations of i
Bharat Forge Signs Long-Term Contract with Embraer for Landing Gear Forgings12.5.2026 18:38:00 CEST | Press release
Bharat Forge Ltd. (BFL) (BSE: 500493, NSE: BHARATFORG), a global leader in advanced forging and precision engineering, today announced a long-term contract with Embraer for the manufacturing and supply of critical landing gear forgings. With this milestone, Bharat Forge becomes the first Indian supplier to join Embraer’s global aerospace supply chain for forged components. Under the agreement, Bharat Forge will supply high-integrity forged components for landing gear systems across Embraer’s commercial and Defence aircraft programs. This engagement establishes a strategic partnership anchored in advanced manufacturing capabilities, precision engineering, and proven expertise in delivering complex, safety-critical components for global aerospace platforms. The long-term contract reflects a shared commitment to quality, reliability, and sustained collaboration, and reinforces Embraer’s confidence in Bharat Forge’s ability to meet stringent global certification standards while consistentl
De' Longhi Group - 6.6% Growth at Constant Exchange Rates and Accelerated Net Profit: Solid Results Fully Support Guidance12.5.2026 18:37:00 CEST | Press release
The Group closed another quarter with robust organic growth, driven by the excellent expansion of the professional division, with turnover growing significantly and representing 18% of the Group's total for the period, and by the positive performance of the household The Board of Directors of De' Longhi S.p.A. approved the consolidated results 1for the first quarter of 2026: In the first quarter the Group achieved: revenues of € 777.7 million, up 3% (+6.6% at constant exchange rates); adjusted 2Ebitda of € 125.9 million, equal to 16.2% of revenues (15.4% in Q1-25); net profit (pertaining to the Group) of € 61.7 million, equal to 7.9% of revenues and up 7.5% compared to the previous year; net financial position at the end of March 2026 of € 720.5 million. CEO Fabio de' Longhi commented: “The start of 2026 was marked by solid revenue growth of 6.6% at constant exchange rates, continuing the excellent performance achieved in recent years. The professional division's strong expansion susta
Multi-Color Corporation Successfully Completes Comprehensive Financial Restructuring12.5.2026 18:09:00 CEST | Press release
Company Emerges Stronger, Well-Positioned to Execute Long-Term Strategy With Significantly Deleveraged Balance Sheet Multi-Color Corporation ("MCC" or the "Company") today announced the successful completion of the Company’s financial restructuring process and emergence from its prepackaged Chapter 11 process. The Company’s prepackaged restructuring reduced net debt by approximately $3.8 billion, reduced annualized cash interest expense by more than $330 million, and extended long-term debt maturities to 2033. More than 99% of voting stakeholders voted to accept MCC’s Plan of Reorganization. Upon emergence, MCC also received a significant $889 million new common and preferred equity investment from CD&R and a group of MCC’s existing secured lenders to support MCC’s long-term growth and investment. "Today marks a significant milestone for MCC, as well as our customers, teammates, and partners who have supported us throughout this process,” said Hassan Rmaile, President and Chief Executi
New Cessna Caravans to Boost USDA’s Fight Against Crop-Damaging Insects12.5.2026 17:00:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced that the U.S. Department of Agriculture (USDA) Animal and Plant Health Inspection Service (APHIS) has ordered three Cessna Caravan aircraft to support its sterile insect release program protecting citrus crops along the Rio Grande River in southern Texas. The new aircraft are expected to be delivered in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512676348/en/ Mission-Ready: The Cessna Caravan joins USDA’s fight to protect Texas citrus from invasive pests APHIS will use the Caravans to carry and release sterile insects that help prevent the spread of destructive pests, including fruit flies. The environmentally friendly technique helps safeguard fruit-bearing trees, reduce crop damage and protect agricultural industries that rely on healthy harvests. “These aircraft will help APHIS reach remote areas and carry out their important mission o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom